- Trial phase
- Phase 1/2a
- Time to market
- Still several years away. The drug is in Phase 1/2a, and assuming successful development, would require at least one later-stage Phase 2b and a Phase 3 program before any regulatory filing, likely 4+ years from now.
- Why 4/10
- ARO-INHBE has no scheduled binary catalyst (PDUFA, Phase 3 readout, or FDA decision) within the next ~12 months, as it remains in Phase 1/2a. The drug is also just one of several pipeline assets at a company with a multi-program platform (plozasiran, ARO-DIMER-PA, ARO-MAPT, ARO-ALK7). Impact score of 4 reflects an early-stage asset without a near-term hard catalyst.
Watch for the next interim Phase 1/2a readout on ARO-INHBE, which could provide longer-term durability and safety data in both monotherapy and tirzepatide-combination arms. Also track Wave Life Sciences' WVE-007 (INHBE siRNA) Phase 2a data, as it is the most advanced direct competitor and could derisk or crowd the target. Arrowhead's broader pipeline catalysts (plozasiran commercialization, ARO-MAPT, ARO-DIMER-PA) may move ARWR stock more than ARO-INHBE in the near term.
Price Chart
Executive Summary
ARO-INHBE is Arrowhead Pharmaceuticals' investigational RNAi therapeutic that silences the INHBE gene (activin E), a genetically validated target linked to fat distribution and metabolic disease risk. It is in a Phase 1/2a trial for obesity and MASH. Early interim data showed that adding ARO-INHBE to Eli Lilly's tirzepatide roughly doubled weight loss at 16 weeks (-9.4% vs -4.8%) and drove robust fat reduction with potential lean muscle preservation. The drug also demonstrated liver fat reduction in MASH patients at EASL 2026. While the early data is promising, the program is still early-stage with no near-term binary regulatory catalyst, and the INHBE-targeting space is growing more competitive (Wave Life Sciences, Rona Therapeutics, Vial). Arrowhead has a much broader pipeline, so ARO-INHBE is not the sole value driver.
How It Works
ARO-INHBE is an RNA interference (RNAi) drug, a type of genetic medicine that silences a specific gene. It targets the INHBE gene in the liver, which produces a protein called activin E that tells the body to store fat. By shutting down that signal, the drug aims to reduce fat mass while better preserving lean muscle compared to existing weight-loss drugs. It is given as a subcutaneous injection.
Trial Status
Arrowhead initiated a Phase 1/2a clinical trial (NCT06700538) in December 2024. Part 1 evaluates single and multiple ascending doses of ARO-INHBE monotherapy; Part 2 tests ARO-INHBE in combination with tirzepatide. Interim results announced in January 2026 showed -9.4% weight loss at 16 weeks for the combination vs -4.8% for tirzepatide alone in obese patients with type 2 diabetes. Further interim data on MASH/liver fat reduction were presented at EASL in May 2026. The study is ongoing.
The Two-Sided Case
Upcoming Catalysts
- Next interim Phase 1/2a data readout (timing not publicly specified as of Nov 2026)
- Potential advancement to Phase 2b studies
- Competitive INHBE data from Wave Life Sciences' WVE-007 Phase 2a trial
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ARROWHEAD PHARMACEUTICALS, INC. 8-K ARWR ·Originating report